BETHESDA, Md., June 20, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE:IGC) announces today that it has filed a patent related to compositions and methods for treating multiple types of seizure disorders and epilepsy for both humans and animals. It involves the utilization of a combination of Phytocannabinoid Cannabidiol (CBD), a Hydantoin anticonvulsant drug and other compounds that affect the metabolism of CBD and Hydantoin drugs.
Approximately 50 million people worldwide are affected by Epilepsy (Sanders, 2003). Epilepsy is thought to be due to multiple factors that include Sodium, Potassium, GABA (gamma amino butyric acid) and NMDA (N-Methyl-d-aspartate). It is believed that to maximally control Epilepsy, modulation of one or more of these receptors is required and that mono therapy is adequate in up to 25% of patients.
Mr. Ram Mukunda, CEO of IGC commented, “We see a significant opportunity in phytocannabinoid-based therapies and this filing complements our portfolio which encompasses the indications of Pain, Medical Refractory Epilepsy and Cachexia. Our plan is to evaluate pre-clinical measures such as testing and toxicity with a specialized firm in Israel to potentially capture cost efficiencies as we continue to build our phytocannabinoid-based based bio-pharmaceutical and nutraceutical IP assets.”
About IGC
In the United States, we develop phytocannabinoid-based therapies and build state-of-the art farming facilities that we can eventually use to grow and extract pharmaceutical grade phytocannabinoids. IGC has several patent filings for the indications of Pain, Medical Refractory Epilepsy and Cachexia using cannabinoids. Internationally, IGC engages in leasing, trading and managing infrastructure projects. We are based in Bethesda, Maryland.
Our website: www.igcinc.us. Twitter @IGCIR Facebook.com/IGCIR/
Forward-looking Statements:
Some of the statements contained in this press release that are not historical facts constitute forward- looking statements under the federal securities laws. Forward-looking statements can be identified by the use of the words "may," "will," "should," "could," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "intends," "potential," "proposed," or the negative of those terms. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond IGC's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, our acquisition and diversification strategy, our competitive environment, and governmental, regulatory, political, economic, legal and social conditions. Except as required by federal securities laws, IGC undertakes no obligation to publicly update any forward- looking statements, whether as a result of new information, future events, or otherwise. Other factors and risks that could cause or contribute to actual results differing materially from such forward- looking statements have been discussed in greater detail in IGC's Form 10- K for fiscal year ended March 31, 2015, and in subsequent reports filed with the U.S. SEC.